July 18, 2016
Bach Pharma Inc. (North Andover, MA) has appointed Kelly Blackburn as Chief Executive Officer.
Kelly Blackburn
Ms. Blackburn was previously Vice President of Clinical Affairs at aTyr Pharma (San Diego, CA). Prior to that she was at Vertex Pharmaceuticals.
Ms. Blackburn is tasked with leading Bach Pharma as it brings its lead candidate, GVT, into the clinic.
The company also announced that Mark O. Henry will serve as Chief Financial Officer, transitioning from his role as CEO.
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
Plan Ahead: Mastering Your AI Budget for 2025 Success
October 9th 2024Generative AI is just one part of the artificial intelligence and machine learning that is being used by life science organizations, emerging as a major area of interest and an area in which costs and ROI are still largely unknown.